Prota Therapeutics: Funding, Investors & Team (Sep 2026)
Prota Therapeutics is a privately-owned biotech company founded in 2016 in Australia. The company's main focus is to develop and market innovative probiotic allergen oral immunotherapy treatments. Prota has exclusive rights to a patented technology for using probiotics in food immunotherapy, which was developed at the MCRI. In order to further their clinical program and establish scalable product manufacturing processes, Prota secured AUD $15m in Series A funding. This funding was provided by OneVentures, a prominent Australian venture capital firm, including a $5m contribution from the Australian Commonwealth Government Biomedical Translation Fund, along with private investments. As a result, Prota is now able to move forward with their plans to conduct a large-scale Phase 3 study on the safety and effectiveness of their PRT100 treatment for peanut allergy. They have also begun discussions with regulatory agencies in preparation for this study.
Prota Therapeutics has raised $21.0M across 1 funding round on record, the most recent an undisclosed round of $21.0M announced in Jan 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Prota Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2024.
Prota Therapeutics Funding Rounds
Prota Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Prota Therapeutics Funding Compared to Other Biotechnology Startups
Prota Therapeutics' latest round of $21.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Prota Therapeutics in Biotechnology and Melbourne
Companies Similar to Prota Therapeutics
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Prota Therapeutics Funding FAQs
What does Prota Therapeutics do?
Prota Therapeutics is a privately-owned biotech company founded in 2016 in Australia. The company's main focus is to develop and market innovative probiotic allergen oral immunotherapy treatments. Prota has exclusive rights to a patented technology for using probiotics in food immunotherapy, which was developed at the MCRI. In order to further their clinical program and establish scalable product manufacturing processes, Prota secured AUD $15m in Series A funding. This funding was provided by OneVentures, a prominent Australian venture capital firm, including a $5m contribution from the Australian Commonwealth Government Biomedical Translation Fund, along with private investments. As a result, Prota is now able to move forward with their plans to conduct a large-scale Phase 3 study on the safety and effectiveness of their PRT100 treatment for peanut allergy. They have also begun discussions with regulatory agencies in preparation for this study.
How much funding has Prota Therapeutics raised?
Prota Therapeutics has raised $21.0M across 1 round on record. The most recent is an undisclosed round of $21.0M announced in Jan 2024.
When did Prota Therapeutics last raise funding?
Prota Therapeutics' most recent funding round on record is an undisclosed round of $21.0M, announced in Jan 2024.
Who founded Prota Therapeutics?
FundedIQ lists Mimi Tang (Founder) at Prota Therapeutics.
Where is Prota Therapeutics headquartered?
Prota Therapeutics is based in Melbourne, Victoria, Australia.
How many employees does Prota Therapeutics have?
Prota Therapeutics is in the 11-50 employee band.
How does Prota Therapeutics' funding compare to other Biotechnology startups?
Prota Therapeutics' latest round of $21.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Prota Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Prota Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.